Skip to content

Study · Animal study (in vivo) · mouse · 2016

7 results

Growth hormone receptor antagonism suppresses tumour regrowth after radiotherapy in an endometrial cancer xenograft model.

Evans A, Jamieson SM, Liu DX, Wilson WR, Perry JK

Cancer letters27 May 2016Cited by 27 (Europe PMC)

PMID27241667 (opens in a new tab)DOI10.1016/j.canlet.2016.05.031 (opens in a new tab)PepBankPUB-27241667
Source linkPubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice, pegvisomant reduced serum IGF1 by 23% compared with vehicle.

    In plain wordsIn mice, pegvisomant reduced serum IGF1 by 23% compared with vehicle.

    Peptide
    Pegvisomant
    Outcome
    DecreaseSerum IGF1
    Study

    mousen: not reported in source

    RL95-2 endometrial tumour xenografts in immunodeficient NIH-III mice
    Comparator
    Vehicle
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    20 mg/kg/day · subcutaneousAs given in this study (mouse).

    Source sentences

    Summary
    Subcutaneous administration of pegvisomant (20 or 100 mg/kg/day, s.c.) reduced serum IGF1 levels by 23% and 68%, respectively, compared to vehicle treated controls.
    1 context sentence
    Summary · context
    RL95-2 xenografts grown in immunodeficient NIH-III mice were treated with vehicle or pegvisomant (100 mg/kg/day), with or without fractionated gamma radiation (10 × 2.5 Gy over 5 days).
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice, pegvisomant reduced serum IGF1 by 68% compared with vehicle.

    In plain wordsIn mice, pegvisomant reduced serum IGF1 by 68% compared with vehicle.

    Peptide
    Pegvisomant
    Outcome
    DecreaseSerum IGF1
    Study

    mousen: not reported in source

    RL95-2 endometrial tumour xenografts in immunodeficient NIH-III mice
    Comparator
    Vehicle
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    100 mg/kg/day · subcutaneousAs given in this study (mouse).

    Source sentences

    Summary
    Subcutaneous administration of pegvisomant (20 or 100 mg/kg/day, s.c.) reduced serum IGF1 levels by 23% and 68%, respectively, compared to vehicle treated controls.
    1 context sentence
    Summary · context
    RL95-2 xenografts grown in immunodeficient NIH-III mice were treated with vehicle or pegvisomant (100 mg/kg/day), with or without fractionated gamma radiation (10 × 2.5 Gy over 5 days).
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In endometrial tumour xenograft mice, adding pegvisomant to radiation increased median tumour tripling time from 49 to 72 days (p = 0.001).

    In plain wordsIn mice with endometrial tumours, pegvisomant plus radiation delayed tumour tripling compared with radiation alone.

    Peptide
    Pegvisomant
    Outcome
    IncreaseTime to triple tumour volume
    Study

    mousen: not reported in source

    RL95-2 endometrial tumour xenografts in immunodeficient NIH-III mice
    Comparator
    Radiation without pegvisomant
    Outcome group
    Tumor growth · Cancer
    Studied dose
    100 mg/kg/day · subcutaneousAs given in this study (mouse).

    Source sentences

    Summary
    When combined with radiation, pegvisomant significantly increased the median time tumours took to reach 3× the pre-radiation treatment volume (49 days versus 72 days; p = 0.001).
    1 context sentence
    Summary · context
    RL95-2 xenografts grown in immunodeficient NIH-III mice were treated with vehicle or pegvisomant (100 mg/kg/day), with or without fractionated gamma radiation (10 × 2.5 Gy over 5 days).
  4. 04AnimalAnimal study (in vivo)Mechanism

    In endometrial tumour xenograft mice, pegvisomant abrogated MAP Kinase signalling throughout the tumour.

    In plain wordsIn mice with endometrial tumours, pegvisomant blocked MAP Kinase signalling throughout the tumour.

    Peptide
    Pegvisomant
    Outcome
    DecreaseTumour MAP Kinase signalling
    Study

    mousen: not reported in source

    RL95-2 endometrial tumour xenografts in immunodeficient NIH-III mice
    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    100 mg/kg every second day · subcutaneousAs given in this study (mouse).

    Source sentences

    Summary
    Immunohistochemistry studies demonstrated that 100 mg/kg pegvisomant every second day was sufficient to abrogate MAP Kinase signalling throughout the tumour.
    1 context sentence
    Summary · context
    RL95-2 xenografts grown in immunodeficient NIH-III mice were treated with vehicle or pegvisomant (100 mg/kg/day), with or without fractionated gamma radiation (10 × 2.5 Gy over 5 days).
  5. 05AnimalAnimal study (in vivo)Mechanism

    In endometrial tumour xenograft mice, pegvisomant increased hypoxic regions in irradiated tumours.

    In plain wordsIn mice with endometrial tumours, adding pegvisomant increased low-oxygen regions compared with radiation alone.

    Peptide
    Pegvisomant
    Outcome
    IncreaseTumour hypoxic regions
    Study

    mousen: not reported in source

    RL95-2 endometrial tumour xenografts in immunodeficient NIH-III mice
    Comparator
    Irradiated tumours without pegvisomant
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated · subcutaneousAs given in this study (mouse).

    Source sentences

    Summary
    In addition, treatment with pegvisomant increased hypoxic regions in irradiated tumours, as determined by immunohistochemical detection of pimonidazole adducts, and decreased the area of CD31 labelling in unirradiated tumours, suggesting an anti-vascular effect.
    1 context sentence
    Summary · context
    RL95-2 xenografts grown in immunodeficient NIH-III mice were treated with vehicle or pegvisomant (100 mg/kg/day), with or without fractionated gamma radiation (10 × 2.5 Gy over 5 days).
  6. 06AnimalAnimal study (in vivo)Mechanism

    In endometrial tumour xenograft mice, pegvisomant decreased CD31 labelling area in unirradiated tumours compared with vehicle.

    In plain wordsIn mice with endometrial tumours, pegvisomant reduced CD31 labelling in unirradiated tumours compared with vehicle.

    Peptide
    Pegvisomant
    Outcome
    DecreaseCD31 labelling area
    Study

    mousen: not reported in source

    RL95-2 endometrial tumour xenografts in immunodeficient NIH-III mice
    Comparator
    Vehicle
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated · subcutaneousAs given in this study (mouse).

    Source sentences

    Summary
    In addition, treatment with pegvisomant increased hypoxic regions in irradiated tumours, as determined by immunohistochemical detection of pimonidazole adducts, and decreased the area of CD31 labelling in unirradiated tumours, suggesting an anti-vascular effect.
    1 context sentence
    Summary · context
    RL95-2 xenografts grown in immunodeficient NIH-III mice were treated with vehicle or pegvisomant (100 mg/kg/day), with or without fractionated gamma radiation (10 × 2.5 Gy over 5 days).
  7. 07AnimalAnimal study (in vivo)Mechanism

    In endometrial tumour xenograft mice, pegvisomant did not affect intratumoral staining for HIF1α, VEGF-A, CD11b or phospho-EGFR.

    In plain wordsIn mice with endometrial tumours, pegvisomant did not change the listed tumour markers compared with vehicle.

    Peptide
    Pegvisomant
    Outcome
    No significant changeHIF1α, VEGF-A, CD11b and phospho-EGFR staining
    Study

    mousen: not reported in source

    RL95-2 endometrial tumour xenografts in immunodeficient NIH-III mice
    Comparator
    Vehicle
    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    Dose not stated · subcutaneousAs given in this study (mouse).

    Source sentences

    Summary
    Pegvisomant did not affect intratumoral staining for HIF1α, VEGF-A, CD11b, or phospho-EGFR.
    1 context sentence
    Summary · context
    RL95-2 xenografts grown in immunodeficient NIH-III mice were treated with vehicle or pegvisomant (100 mg/kg/day), with or without fractionated gamma radiation (10 × 2.5 Gy over 5 days).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:34 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.